AVACEN Announces Breakthrough Migraine Treatment Results and Launch of Clinical Trial

Share Article

AVACEN, Inc., today announced breakthrough migraine treatment results from a 6 month pre-clinical trial evaluation of patients using rapid body core temperature heating and the launch of a more extensive clinical trial to further authenticate the capabilities of its patented non-invasive, rapid body core heating Normalizerâ„¢ device.

AVACEN, Inc., today announced breakthrough migraine treatment results from a 6 month pre-clinical trial evaluation of patients using rapid body core temperature heating and the launch of a more extensive clinical trial to further authenticate the capabilities of its patented non-invasive, rapid body core heating Normalizerâ„¢ device.

"We are very excited to begin the systemic scientific evaluation of our Normalizer device for the treatment of Migraines which affect over 30 million Americans," said Thomas Muehlbauer, Chief Executive Officer of AVACEN, Inc. "We believe that this trial will build significantly on the data generated by our previous successful treatment of patients with migraine histories ranging from 1 to 20 years."

The 13 week clinical trial will enroll migraine sufferers between the ages of 18 to 78. This is an open, randomized, cross-over study to investigate the efficacy of the AVACEN Normalizer Device
Muehlbauer continued, "Although the use of the Normalizer device on patients in the pre-clinical evaluation was 100% positive, the most dramatic results were witnessed in a female who had experienced debilitating weekly migraines for over 20 years. Beginning with her first treatment, we were able avert her migraines with a single Normalizer treatment at the onset of the aura. An unexpected result was the expanded time between onsets of the auras. Initially the Normalizer was used multiple times a week which stretched to weekly, bi-weekly, monthly and then the auras and migraines just stopped about 3 months ago!"

AVACEN believes that, by scientifically documenting the results of the Normalizer it will be able to more rapidly foster the recognition of the Normalizer as an accepted method for improving the quality of life in migraine patients.

About Migraines

Migraine headaches affect approximately 30 million people in the United States. Of those who suffer from migraines less than half are properly diagnosed with the condition. Migraines most commonly occur between the ages of 30 and 49, a time when people are actively involved in the workforce (productivity losses due to migraines in the U.S. are estimated at $29 Billion annually).

About AVACEN, Inc.

The Company's product, the Normalizerâ„¢, is a patented device which is available in a "Clinic" version or "Personal" model for home use. The Normalizer non-invasively and rapidly infuses heat into, or extracts heat from, the blood stream in order to quickly adjust low or high core body temperature towards normothermia (approximately 98.6 °F). Moving the body towards normothermia for those with low or high body temperature can provide remarkable results in 3 to 10 minutes for disease symptoms such as migraines, metabolic disorders such as weight loss resistance, temperature emergencies such as heat stroke, neurologic disorders such as Multiple Sclerosis and performance limiting muscle fatigue. For more information, visit http://www.AVACEN.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Thomas Muehlbauer
AVACEN, Inc.
888-428-2236 ext. 701
Email >
Visit website